Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Update

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) saw a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 2,420,000 shares, a decrease of 18.0% from the January 15th total of 2,950,000 shares. Currently, 1.9% of the company’s shares are short sold. Based on an average daily trading volume, of 1,200,000 shares, the days-to-cover ratio is presently 2.0 days.

Insider Activity

In other news, Director Gautam Patel sold 62,590 shares of the firm’s stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $8.01, for a total transaction of $501,345.90. Following the completion of the sale, the director now owns 1,968,886 shares of the company’s stock, valued at $15,770,776.86. This trade represents a 3.08 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders sold 160,000 shares of company stock valued at $1,292,000 over the last quarter. 26.56% of the stock is owned by company insiders.

Institutional Trading of Amneal Pharmaceuticals

Large investors have recently modified their holdings of the business. JPMorgan Chase & Co. boosted its position in shares of Amneal Pharmaceuticals by 149.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,297,094 shares of the company’s stock valued at $10,792,000 after acquiring an additional 777,568 shares during the last quarter. Barclays PLC boosted its position in shares of Amneal Pharmaceuticals by 134.1% during the 3rd quarter. Barclays PLC now owns 296,384 shares of the company’s stock valued at $2,466,000 after acquiring an additional 169,756 shares during the last quarter. State Street Corp boosted its position in shares of Amneal Pharmaceuticals by 3.8% during the 3rd quarter. State Street Corp now owns 3,514,721 shares of the company’s stock valued at $29,242,000 after acquiring an additional 127,753 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in shares of Amneal Pharmaceuticals during the 4th quarter valued at about $520,000. Finally, Geode Capital Management LLC lifted its position in Amneal Pharmaceuticals by 11.1% in the 3rd quarter. Geode Capital Management LLC now owns 3,786,671 shares of the company’s stock worth $31,511,000 after buying an additional 378,136 shares during the last quarter. Institutional investors own 31.82% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. StockNews.com cut Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, December 19th. Piper Sandler increased their target price on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an “overweight” rating in a report on Monday, November 11th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $10.00.

Amneal Pharmaceuticals Price Performance

AMRX stock traded down $0.18 during mid-day trading on Friday, reaching $7.73. 484,881 shares of the company traded hands, compared to its average volume of 1,200,624. The company has a market capitalization of $2.40 billion, a P/E ratio of -11.37 and a beta of 1.10. Amneal Pharmaceuticals has a 52-week low of $5.01 and a 52-week high of $9.48. The company has a fifty day moving average price of $8.06 and a 200-day moving average price of $8.26.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.